ANASTASIA FRAZIER: Open Payments
NPI 1790407831 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$705 in 37 payments from 12 companies in 2025. Trend: 2023 $247 · 2024 $435 · 2025 $705
Food & beverage: $705
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 14 | $198 |
| Novartis Pharmaceuticals Corporation | 4 | $89 |
| PFIZER INC. | 4 | $85 |
| ABIOMED | 2 | $71 |
| Merck Sharp & Dohme LLC | 3 | $65 |
| Philips North America LLC | 1 | $47 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 3 | $38 |
| Amgen Inc. | 2 | $33 |
| Novo Nordisk Inc | 1 | $26 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
Products named: CAMZYOS, LEQVIO, VYNDAQEL, VERQUVO, Ambulatory Monitoring & Diagnostics Undivided, LifeVest, REPATHA, ELIQUIS.
Industry payments across AL — which companies pay providers there.
